University Children's Hospital, Department of Hematology & Oncology, Faculty of Medicine, University of Belgrade, Dr Subotica 13, 11000 Belgrade, Serbia.
Biomark Med. 2013 Oct;7(5):791-801. doi: 10.2217/bmm.13.84.
Pediatric non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of malignancies with distinct clinical, pathological, immunological and genetic characteristics. More than 90% of pediatric NHLs belong to one of three major histological subtypes: mature B-cell neoplasms, lymphoblastic lymphomas and anaplastic large-cell lymphomas. The recognition that different subtypes require different treatment regimens resulted in therapeutic strategies leading to over 80% of patients being cured. On the other hand, patients with resistant or relapsed disease have a poor prognosis. Prognostic biomarkers have not yet been identified for all pediatric NHLs and, although some are very important for diagnosis and prognosis, others may be of questionable value. Discovery of new biomarkers suitable for clinical application may aid the diagnosis and classification of lymphomas, which should, in turn, lead to better patient stratification. Consequent development of new treatment and follow-up approaches should lead to more efficient and less toxic treatment in children with NHL.
儿科非霍奇金淋巴瘤（NHL）是一组具有不同临床、病理、免疫和遗传特征的恶性肿瘤。超过 90%的儿科 NHL 属于三种主要组织学亚型之一：成熟 B 细胞肿瘤、淋巴母细胞淋巴瘤和间变大细胞淋巴瘤。认识到不同亚型需要不同的治疗方案，导致了治疗策略的发展，使超过 80%的患者得以治愈。另一方面，耐药或复发的患者预后较差。并非所有儿科 NHL 都能确定预后生物标志物，尽管有些对诊断和预后非常重要，但其他标志物可能价值存疑。发现适合临床应用的新生物标志物可能有助于淋巴瘤的诊断和分类，进而实现更好的患者分层。随后开发新的治疗和随访方法，应该会使 NHL 患儿的治疗更加高效、毒性更小。
